Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 33 clinical trials
Inducing Immune Quiescence the Genital Tract With ASA (IIQ-2)

activated T cells, increased levels of systemic T regulatory, increased production of anti-viral anti-protease serpins at the female genital tract and reduced numbers of HIV target cells (mainly CD4+ CCR5

AIDS
protease
HIV Vaccine
Accepts healthy volunteers
  • 0 views
  • 22 Mar, 2022
  • 1 location
Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL

joined to a T cell in this way it is called a chimeric receptor. These CD30 chimeric (combination) receptor-activated T cells seem to kill some of the tumor, but they do not last very long in the body

lymphoma cell count
stem cell transplantation
neutrophil count
gilbert's syndrome
tumor cells
  • 92 views
  • 24 Feb, 2022
  • 1 location
Study of ATLCAR.CD138 Cells for Relapsed/Refractory Multiple Myeloma

the entire antibody. When an antibody is joined to a T cell in this way it is called a chimeric receptor. These CD138 chimeric (combination) receptor-activated T cells seem to kill some of the tumor

prednisone
neutrophil count
refractory multiple myeloma
tumor cells
cell transplantation
  • 37 views
  • 04 Oct, 2022
  • 1 location
Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

is called a chimeric receptor. The kappa light chain chimeric (combination) receptor-activated T cells are called ATLCAR..28 cells. These cells may be able to destroy lymphoma cancer cells. They do

monoclonal antibodies
anti-cd20 monoclonal antibody
lymphoma cells
bendamustine
alkylating agent
  • 15 views
  • 09 Dec, 2021
  • 1 location
CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30) (RELY-30)

the T cells. When an antibody is joined to a T cell in this way it is called a chimeric receptor. These CD30 chimeric receptor-activated T cells (CD30.CAR T cells) seem to kill some of the tumor, but

lymphoma cell count
pulse oximetry
chemotherapy drugs
autologous transplantation
cancer
  • 46 views
  • 04 Oct, 2022
  • 2 locations
Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma

antibody is joined to a T cell in this way it is called a chimeric receptor. These CD19 chimeric (combination) receptor-activated T cells seem to kill some of the tumor, but they do not last very long in

stem cell transplantation
monoclonal antibodies
b-cell lymphoma
refractory b-cell non-hodgkin lymphoma
remission
  • 0 views
  • 04 Feb, 2022
  • 1 location
Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL

chimeric receptor. These CD30 chimeric (combination) receptor-activated T cells (ATLCAR.CD30) can kill some of the tumor, but they do not last very long in the body and so their chances of fighting the

stem cell transplantation
b-cell lymphoma
tumor cells
anaplastic large cell lymphoma
expression by immunohistochemistry
  • 323 views
  • 25 May, 2022
  • 1 location
Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL

cell in this way it is called a chimeric receptor. These CD19 chimeric (combination) receptor-activated T cells kill some of the tumor, but they do not last very long in the body and so their chances

stem cell transplantation
t315i mutation
blinatumomab
remission
tyrosine
  • 28 views
  • 21 Mar, 2022
  • 1 location
Neihulizumab (ALTB-168) in Patients With Steroid-refractory Acute Graft-versus-host Disease or Treatment-refractory Acute Graft-versus-host Disease

A Phase I study to establish the pharmacokinetics, pharmacodynamics, safety and efficacy profiles of Neihulizumab in patients with steroid-refractory or treatment refractory acute graft-versus-host disease (SR/TR-aGVHD)

  • 32 views
  • 04 Oct, 2022
  • 1 location
ADG126, ADG126 in Combination With Anti PD1 Antibody, and ADG126 in Combination With ADG106 in Advanced/Metastatic Solid Tumors

ADG126, ADG126 in Combination with anti-PD1 antibody, and ADG126 in Combination with ADG106 in Patients with Advanced/Metastatic Solid Tumors .

  • 0 views
  • 07 Jun, 2022
  • 4 locations